Frontier Pharma First-In-Class Innovation in Hematological Cancers First-in-Class Innovation in Hematological Cancers

Frontier Pharma: First-in-Class Innovation in
Hematological Cancers - Cytokine Signaling
and Kinase Targeted Immunotherapies
Dominate a Large and Highly Versatile
Pipeline
“The American Cancer Society (ACS) predicts that in
2017 there will be almost 173,000 new cases of
leukemia, lymphoma and myeloma, with lymphomas
the most prevalent.”
Summary
The American Cancer Society (ACS) predicts that in 2017 there will be almost 173,000 new cases
of leukemia, lymphoma and myeloma, with lymphomas the most prevalent. Due to a degree of
crossover between hematological malignancies in terms of their underlying pathophysiology, it is
not uncommon for products being developed for this therapy area to have developmental programs
testing them across multiple indications.
The report assesses versatile and first-in-class innovation in the hematological cancer pipeline,
highlighting key trends in first-in-class product distribution.
Read Complete Report with TOC @ http://www.radiantinsights.com/research/frontier-
pharma--first-in-class-innovation-in-hematological-cancers
Follow Us: